AstraZeneca on Monday announced that the EU drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, Sipavibart, under an accelerated assessment.
According to the company’s press statement, the submission was based on positive data from a late-stage trial that showed the drug helped reduce the incidence of COVID-19 in immunocompromised patients.
(With inputs from Reuters)
Read more on financialexpress.com